PELOTON THERAPEUTICS, INC.

(PLTX)
End-of-day quote Nasdaq  - 
0.000000 USD    0.00%
2019Peloton Therapeutics, Inc. has withdrawn its IPO in the amount of $159.375 million.
CI
2019Peloton Therapeutics Announces Board Changes
CI
2019Peloton Therapeutics, Inc. has filed an IPO in the amount of $115 million.
CI
 SummaryQuotesNewsCompany 
Company
Peloton Therapeutics, Inc. is a clinical stage pharmaceutical company. The Company is focused on developing medicines for patients with cancer and other conditions. The Company's product pipeline includes Hypoxia-inducible factor-2α (HIF-2α). HIF-2α is a transcription factor that, in part, regulates the body’s response to diminished availability of oxygen. The Company’s lead drug candidate, PT2977, is an oral... 
More about the company
All news about PELOTON THERAPEUTICS, INC.
2019Peloton Therapeutics, Inc. has withdrawn its IPO in the amount of $159.375 million.
CI
2019Peloton Therapeutics Announces Board Changes
CI
2019Peloton Therapeutics, Inc. has filed an IPO in the amount of $115 million.
CI
2019Peloton Therapeutics To Seek Acquisitions
CI
2019Peloton Therapeutics, Inc. announced that it has received $150 million in funding from ..
CI
2018Peloton Therapeutics Announces Appointment of John Moore as General Counsel and Corpora..
CI
2018Peloton Therapeutics, Inc. Appoints Alan A. Musso as Chief Financial Officer
CI
2018Peloton Therapeutics Initiates Phase 2 Trial of OralHIF-2a Inhibitor PT2977 for Treatme..
CI
2018Peloton Therapeutics, Inc. Announces Board Changes
CI
2017Peloton Therapeutics, Inc. Announces Results from A Phase 1 Study Evaluating PT2385 in ..
CI
2017Peloton Therapeutics, Inc. Initiates Patient Dosing in Phase 2 Study of PT2385 for Von ..
CI
2017Peloton Therapeutics, Inc. Appoints Mohammad Hirmand as Chief Medical Officer, Effectiv..
CI
2017Peloton Therapeutics, Inc. announced that it has received $74.6 million in funding from..
CI
2016Peloton Therapeutics, Inc. announced that it expects to receive $52.4 million in fundin..
CI
2016Peloton Therapeutics, Inc. Presents Clinical Data on First-In-Class Oral HIF-2a Inhibit..
CI
More news
News in other languages on PELOTON THERAPEUTICS, INC.

- No features available -

More news
Managers and Directors
John A. Josey President, Chief Executive Officer & Director
Alan A. Musso Chief Financial Officer
David V. Goeddel Chairman
Naseem Zojwalla Head-Clinical Development & Strategy
Brett A. Ringle Director
Sector and Competitors
1st jan.Capi. (M$)
PELOTON THERAPEUTICS, INC.0.00%711
GILEAD SCIENCES, INC.-14.10%78 232
REGENERON PHARMACEUTICALS, INC.2.22%69 552
VERTEX PHARMACEUTICALS12.35%63 100
WUXI APPTEC CO., LTD.-16.67%43 023
BIONTECH SE-38.39%38 601